Clinical Trial Update: A Safety and Efficacy Study of OnabotulinumtoxinA in Premature Ejaculation [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the safety and efficacy of onabotulinumtoxinA for premature ejaculation has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Premature Ejaculation

Drugs mentioned

• OnabotulinumtoxinA (botulinum toxin type A)

Snippet

Sponsor: Allergan | Conditions: Premature Ejaculation | Phase 2 | Status: TERMINATED | Results posted: 2018-10-18